Literature DB >> 8813223

Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.

R Pahwa1, J Marjama, D McGuire, K Lyons, F Zwiebel, P Silverstein, R Ward, W C Koller.   

Abstract

We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single-dose double-blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, or walking time. In this single-dose study, there were no significant differences in pharmacokinetic and motor responses between Sinemet and Atamet.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813223     DOI: 10.1002/mds.870110412

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

1.  Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).

Authors:  Margherita Torti; Jhessica Alessandroni; Daniele Bravi; Miriam Casali; Paola Grassini; Chiara Fossati; Cristiano Ialongo; Marco Onofrj; Fabiana Giada Radicati; Laura Vacca; Stefano Bonassi; Fabrizio Stocchi
Journal:  Br J Clin Pharmacol       Date:  2019-09-12       Impact factor: 4.335

2.  Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment.

Authors:  Narongrit Kasemsap; Satrirat Onsanit; Piyawan Chiewthanakul; Kannikar Kongbunkiat; Chonthicha Tanking; Nisa Vorasoot; Kittisak Sawanyawisuth; Somsak Tiamkao
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-11       Impact factor: 2.570

3.  Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.

Authors:  Urs E Gasser; Anton Fischer; Jan P Timmermans; Isabelle Arnet
Journal:  BMC Pharmacol Toxicol       Date:  2013-04-23       Impact factor: 2.483

4.  Are branded and generic extended-release ropinirole formulations equally efficacious? A rater-blinded, switch-over, multicenter study.

Authors:  Edit Bosnyák; Mihály Herceg; Endre Pál; Zsuzsanna Aschermann; József Janszky; Ildikó Késmárki; Sámuel Komoly; Kázmér Karádi; Tamás Dóczi; Ferenc Nagy; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2014-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.